Descovy (TAF and EM) Vs Triumeq (Dolutegravir + Lamivudine + Abacavir)

Descovy contains emtricitabine that is similar in chemical composition to lamivudine contained in Triumeq as both are cytidine analogs. As a result, using both drugs simultaneously may put one at risk of intracellular interactions. Seek advice from a healthcare professional for more detailed information.

What Is Descovy?

Descovy is a two-drug HIV medication comprising of tenofovir alafenamide and emtricitabine, both in specified doses. It improves the health standard of patients by lowering the amount of the virus in the blood. Descovy is not a cure for HIV but a good control measure for the infection. Correct and continuous usage may help users achieve an undetectable viral load.

Tenofovir alafenamide is considered a prodrug of tenofovir. Both active ingredients belong to the group of nucleoside/nucleotide reverse transcriptase inhibitors that act on the reverse transcriptase enzyme of the virus.

Descovy used for the treatment of HIV-1 infection should not be taken by patients weighing less than 25 kg. Furthermore, those using it for PrEP must weigh 35 Kg at least [1]. Descovy can be prescribed for adults and adolescents alike.

What Is Triumeq?

Triumeq is a triple-combination antiretroviral medication consisting of dolutegravir, lamivudine, and abacavir as its active ingredients. It helps lower the level of infection in the blood, and this ultimately improves the immune system, making it more active against infection [2].

While one of its ingredients, dolutegravir, belongs to a class of drugs known as integrase inhibitors, lamivudine and abacavir belong to nucleoside reverse transcriptase inhibitors (NRTIs).

All three antiretroviral substances interfere with the actions of enzymes (integrase and reverse transcriptase enzymes) needed by the virus to make copies of itself. Triumeq is a complete treatment in one pill and is recommended for use once daily [3].

Drug Comparison: Descovy Vs Triumeq

Unlike Descovy that may be combined with other antiretroviral drugs for improved effectiveness, Triumeq works effectively as a stand-alone drug.

Both meds contain active ingredients that belong to the same class of inhibitors, and this makes their joint usage a bad idea. Using these drugs together may increase the possibility of adverse effects and even lead to severe health complications. It is advisable to consult a healthcare provider for more information about both drugs, their possible interactions, and a suitable treatment regiment.


  1. DESCOVY® (emtricitabine and tenofovir alafenamide) tablets, for oral use. HIGHLIGHTS OF PRESCRIBING INFORMATION (pdf).
  2. Triumeq®.
  3. Triumeq. Sean R. Hosein. Published 2018.
It may be useful for you